Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study

Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study

Abstract Objective We aimed to retrospectively evaluate the safety and efficacy of tislelizumab combined with the gemcitabine and cisplatin (GP) regimen as neoadjuvant therapy followed by nimotuzumab with concurrent chemoradiotherapy (CCRT) for locoregionally advanced nasopharyngeal carcinoma (LANPC...

Full description

Saved in:
Bibliographic Details
Main Authors: Mingfen Lai, Shuai Li, Zhongwen Jin, Mingzhang Chang, Fangming Li, Peixin Yang, Yiming He, Qinhua Zhang
Format: Article
Language:English
Published: Springer 2025-06-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Neoadjuvant therapy
Tislelizumab
Nimotuzumab
Locoregionally advanced nasopharyngeal carcinoma
Concurrent chemoradiotherapy
Online Access:https://doi.org/10.1007/s00262-025-04100-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04100-5

Similar Items